EYPT

EyePoint Inc

0.3612

Nov 02 • 1:48 PM ET +0.0128 (3.67%)

Healthcare Biotechnology USA Nano NASD

Peers: OCUL KOD SGP FDMT OTLK RGNX OCS SRZN BLTE TARS

| Held by: VTI VXF VTWO IWM VHT XPH VTWG IWO SCHA DFAS

Index	RUT
Market Cap	31.14M
Enterprise Value	-126.96M
Income	-306.64M
Sales	2.79M
Book/sh	1.96
Cash/sh	2.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	214
IPO	Jan 27, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	11.16
P/B	0.18
P/C	0.17
P/FCF	-
EV/EBITDA	-
EV/Sales	-45.50
Quick Ratio	4.46
Current Ratio	4.50
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-3.74
EPS next Y	-2.14
EPS next Q	-0.93
EPS this Y	-14.57%
EPS next Y	41.22%
EPS next 5Y	27.67%
EPS past 3/5Y	-4.94% 2.18%
Sales past 3/5Y	-8.83% -1.85%
EPS Y/Y TTM	-39.78%
Sales Y/Y TTM	-94.63%
EPS Q/Q	-28.45%
Sales Q/Q	-90.49%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-10.82% 14.45%

Insider Own	6.38%
Insider Trans	0.10%
Inst Own	123.66%
Inst Trans	9.60%
ROA	-115.86%
ROE	-148.70%
ROIC	-164.66%
Gross Margin	-18.29%
Oper. Margin	-11365.22%
Profit Margin	-10994.73%
SMA20	-78.23%
SMA50	-88.38%
SMA200	-96.69%
Trades

Shs Outstand	84.98M
Shs Float	80.71M
Short Float	26.34%
Short Ratio	2.38
Short Interest	21.26M
52W High	19.11 -98.11%
52W Low	0.34 4.82%
Volatility	10.23% 10.38%
ATR (14)	0.24
RSI (14)	16.08
Beta	1.85
Rel Volume	0.51
Avg Volume	8.93M
Volume	3,078,187

Perf Week	-1.23%
Perf Month	-88.89%
Perf Quarter	-96.90%
Perf Half Y	-97.39%
Perf YTD	-98.02%
Perf Year	-97.24%
Perf 3Y	-95.05%
Perf 5Y	-97.05%
Perf 10Y	-98.11%
Recom	2.54
Target Price	12.39
Prev Close	0.35
Price	0.36
Change %	3.67%

Consensus

Hold

Avg. Price Target

$12.39

Implied Upside

+3,330.2%

Analysts14incl. previous ratings

Rating Distribution5 Buy · 8 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Downgrade	MMizuho	Outperform → Neutral	$0.50	+38.4%
Oct 20, 2026	Downgrade	JJP Morgan	Neutral → Underweight
Oct 19, 2026	Downgrade	JJefferies	Buy → Hold	$1	+176.9%
Oct 19, 2026	Downgrade	GGuggenheim	Buy → Neutral
Sep 02, 2026	Downgrade	TTD Cowen	Buy → Hold	$4	+1,007.4%
Aug 18, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$5	+1,284.3%
Aug 18, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Aug 18, 2026	Downgrade	CChardan Capital Markets	Buy → Neutral	$5	+1,284.3%
Aug 17, 2026	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Jul 16, 2026	Initiated	SStifel	Buy	$40	+10,974.2%
Jul 08, 2026	Resumed	CCantor Fitzgerald	Overweight	$47	+12,912.2%
Jun 17, 2025	Initiated	RRBC Capital Mkts	Outperform	$28	+7,651.9%
Jan 07, 2025	Initiated	CCitigroup	Buy	$33	+9,036.2%
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Aug 28, 2024	Initiated	JJefferies	Buy	$15	+4,052.8%
Jan 22, 2024	Initiated	JJP Morgan	Overweight	$35	+9,589.9%
Nov 02, 2023	Initiated	MMizuho	Buy	$20	+5,437.1%
Apr 21, 2023	Initiated	RRobert W. Baird	Outperform	$33	+9,036.2%
Jul 07, 2022	Initiated	CChardan Capital Markets	Buy	$21	+5,714.0%
Mar 01, 2021	Initiated	CCowen	Outperform	$25	+6,821.4%

Oct-20-26 07:37AM	EyePoint halves workforce and ends Phase III trial early after endpoint miss (Clinical Trials Arena) -7.91%
Oct-19-26 10:39PM	Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today? (Stocktwits) -85.28%
09:58AM	EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut (Investing.com)
08:47AM	EyePoint Announces 53% Workforce Reduction Following Phase 3 DURAVYU Trial Results (InvestorsHub)
08:19AM	This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope. (Barrons.com)
07:15AM	Loading…
07:15AM	EyePoint Announces Strategic Prioritization (GlobeNewswire)
07:00AM	EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU in Wet AMD (GlobeNewswire)
Sep-28-26 01:15PM	OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits) -8.56%
Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
Sep-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.74%
Sep-06-26 06:30AM	Street Calls of the Week (Investing.com)
Sep-02-26 09:54AM	Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting (GlobeNewswire)
Aug-24-26 08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com) -8.46%
Aug-18-26 10:40AM	EyePoints Duravyu falls short to Eylea in Phase III trial (Clinical Trials Arena) +12.32%
09:37AM	Loading…
09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly)
07:57AM	EyePoints Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says Retail Calls EYPT Slump A Huge Overreaction (Stocktwits)
Aug-17-26 11:00PM	Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -66.98%
07:51PM	OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits)
11:14AM	EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. (Barrons.com)
10:56AM	EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden (InvestorsHub)
09:41AM	The Surprising Reason EyePoint Just Crashed 69% (Investor's Business Daily)
09:19AM	EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback Retail Sees Ocular Therapeutics As A Better Buyout Candidate (Stocktwits)
07:00AM	EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD (GlobeNewswire)
Aug-14-26 04:32PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +9.42%
Aug-05-26 07:33AM	EyePoint: Q2 Earnings Snapshot (Associated Press)
07:00AM	EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-30-26 07:00AM	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) (GlobeNewswire) +7.89%
Jul-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.85%
Jul-13-26 07:00AM	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer (GlobeNewswire)
07:00AM	Loading…
Jun-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.62%
May-19-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-18-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.26%
May-14-26 07:00AM	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data (GlobeNewswire)
May-06-26 07:21AM	EyePoint: Q1 Earnings Snapshot (Associated Press)
07:00AM	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-29-26 07:00AM	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Apr-16-26 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-26 06:12PM	EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)
Mar-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 04:03PM	EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... (GuruFocus.com) -12.44%
10:36AM	Eyepoint Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:23AM	EyePoint: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-02-26 07:00AM	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-26-26 12:15PM	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-25-26 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
07:00AM	EyePoint Appoints Michael Campbell as Chief Commercial Officer (GlobeNewswire)
Feb-17-26 08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com) +15.22%
07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-13-26 05:12PM	EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program (MarketBeat) +15.22%
Feb-05-26 07:00AM	EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 07:00AM	EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 (GlobeNewswire)
Dec-22-25 12:00PM	EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know (Zacks) +8.15%
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-17-25 07:00AM	EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	Director	Aug 18 '26	Buy	4.93	10,600	52,258	49,100	Aug 18 04:08 PM
Lurker Nancy	Officer	Jul 21 '26	Proposed Sale	13.05	421,235	5,497,117		Jul 21 04:44 PM
Duker Jay S.	President and CEO	Jul 10 '26	Option Exercise	0.00	16,667	0	17,653	Jul 14 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jun 30 '26	Option Exercise	8.26	4,875	40,268	4,875	Jul 02 04:03 PM
Ribeiro Ramiro	Chief Medical Officer	Jun 30 '26	Sale	15.01	4,875	73,167	0	Jul 02 04:03 PM
Elston George	Chief Financial Officer	May 25 '26	Option Exercise	0.00	7,500	0	95,318	May 27 04:05 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Apr 20 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Apr 17 '26	Sale	15.00	2,437	36,555	0	Apr 20 04:07 PM
Ramiro Ribeiro	Officer	Apr 17 '26	Proposed Sale	14.81	9,750	144,398		Apr 17 04:36 PM
Duker Jay S.	President and CEO	Mar 16 '26	Buy	13.15	1,500	19,724	100,665	Mar 16 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Option Exercise	8.26	2,438	20,138	2,438	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Mar 04 '26	Sale	17.87	2,438	43,572	0	Mar 05 04:02 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Option Exercise	8.26	2,437	20,130	2,437	Feb 18 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Feb 17 '26	Sale	15.00	2,437	36,555	0	Feb 18 04:07 PM
Lurker Nancy	Director	Jan 06 '26	Option Exercise	0.00	75,133	0	294,346	Jan 07 04:13 PM
Duker Jay S.	President and CEO	Jan 06 '26	Option Exercise	0.00	20,793	0	87,806	Jan 07 04:12 PM
Elston George	Chief Financial Officer	Jan 06 '26	Option Exercise	0.00	15,285	0	96,339	Jan 07 04:12 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Option Exercise	8.26	29,250	241,605	42,544	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 05 '26	Sale	17.10	42,544	727,319	0	Jan 07 04:07 PM
Ribeiro Ramiro	Chief Medical Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	19,667	Jan 06 04:47 PM
Duker Jay S.	President and CEO	Jan 05 '26	Option Exercise	0.00	30,000	0	81,518	Jan 06 04:10 PM
Duker Jay S.	President and CEO	Jan 03 '26	Option Exercise	0.00	65,000	0	74,965	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	15,000	0	85,457	Jan 06 04:10 PM
Elston George	Chief Financial Officer	Jan 03 '26	Option Exercise	0.00	19,667	0	76,781	Jan 06 04:10 PM
Lurker Nancy	Director	Jan 05 '26	Option Exercise	0.00	12,666	0	219,213	Jan 06 04:07 PM
Ramiro Ribeiro	Officer	Jan 05 '26	Proposed Sale	17.48	53,792	940,284		Jan 05 04:42 PM
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

PresidentDr. Jay S. Duker M.D.

Executive VP & CFOMr. George O. Elston CPA

Ph.D.Dr. Ramiro Ribeiro M.D.

Chief Scientific OfficerDr. Marcia Sellos-Moura Ph.D.

Chief Legal Officer & Company SecretaryMr. Ron I. Honig Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EYPT

EyePoint Inc

Upgrade your Finviz experience